Matinas BioPharma Holdings, Inc.

Rentabilité sur six mois: +33.12%
Rendement en dividendes: 0%
Secteur: Healthcare

0.84 $

0 $ 0%
0.0933 $
4.12 $

paper.min_max_per_year

Calendrier des promotions Matinas BioPharma Holdings, Inc.

À propos de l'entreprise Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Paramètres de base

IPO date
2014-08-18
ISIN
US5768101058
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 43.41 1
P/BV 0.3321 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -128.5 0
ROE -180.73 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.1239 10
Debt/Ratio 0.2289 10
Debt/Equity 0.6655 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 1117.78 10
Rentabilité Ebitda, % -7.67 0
Rentabilité EPS, % 4664.76 10

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.84 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.04 $ 0 $ 0 $ -19.23 % 0 % 0 %
common.calendar.number_days.30d 0.812 $ 0.84 $ 1.04 $ 3.45 % 0 % 0 %
common.calendar.number_days.90d 0.54 $ 0.5127 $ 1.04 $ 55.56 % 0 % 0 %
common.calendar.number_days.180d 0.631 $ 0.5127 $ 1.04 $ 33.12 % 0 % 0 %
common.calendar.number_days.1y 0.0933 $ 0.0933 $ 4.12 $ 800.32 % 0 % 0 %
common.calendar.number_days.3y 0.7 $ 0.0933 $ 4.12 $ 20 % 0 % 0 %
common.calendar.number_days.5y 0.8095 $ 0.0933 $ 4.12 $ 3.77 % 0 % 0 %
common.calendar.number_days.10y 0.0933 $ 0.0933 $ 4.12 $ 900.32 % 0 % 0 %
common.calendar.number_days.ytd 0.574 $ 0.5127 $ 1.04 $ 46.34 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Jerome D. Jabbour J.D. Co-Founder, CEO, President & Director 842.38k 1974 (51 année)
Dr. Theresa Matkovits Ph.D. Chief Development Officer 570.08k 1967 (58 années)
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer 621k 1954 (71 année)
Mr. Keith A. Kucinski CPA, M.B.A. Chief Financial Officer 249.05k 1970 (55 années)
Dr. Hui Liu M.B.A., Ph.D. Chief Technology Officer N/A 1968 (57 années)
Mr. Frank Calamusa Executive Director and Head of Manufacturing & Supply Chain N/A
Mr. Thomas J. Hoover M.B.A. Chief Business Officer N/A 1970 (55 années)

Informations sur l'entreprise

Adresse: United States, Bedminster. NJ, 1545 Route 206 South - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.matinasbiopharma.com